Royal Bank of Canada
SVA

Royal Bank of Canada’s Sinovac Biotech, Ltd SVA Stock Holding History

Royal Bank of Canada’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
426
+1
+0.2% – ﹤0.01% 7893
2025
Q4 		$0 Hold
425
– – ﹤0.01% 7823
2025
Q3 		$0 Hold
425
– – ﹤0.01% 7674
2025
Q2 		$0 Buy
+425
New – ﹤0.01% 7514
2024
Q3 		– Sell
-442
Closed – – 7778
2024
Q2 		$0 Sell
442
-91
-17% – ﹤0.01% 7820
2024
Q1 		$0 Buy
+533
New – ﹤0.01% 7903
2023
Q4 		– Sell
-533
Closed – – 7936
2023
Q3 		$0 Hold
533
– – ﹤0.01% 8005
2023
Q2 		$0 Buy
+533
New – ﹤0.01% 8032
2022
Q4 		– Sell
-516
Closed – – 8247
2022
Q3 		$0 Hold
516
– – ﹤0.01% 8294
2022
Q2 		$0 Buy
+516
New – ﹤0.01% 8267
2022
Q1 		– Sell
-516
Closed – – 8351
2021
Q4 		$0 Buy
516
+85
+20% – ﹤0.01% 8347
2021
Q3 		$0 Hold
431
– – ﹤0.01% 8223
2021
Q2 		$0 Sell
431
-9
-2% – ﹤0.01% 8035
2021
Q1 		$0 Hold
440
– – ﹤0.01% 7990
2020
Q4 		$0 Buy
440
+21
+5% – ﹤0.01% 7563
2020
Q3 		$0 Buy
+419
New – ﹤0.01% 7303
2020
Q2 		– Sell
-10,000
Closed – – 7223
2020
Q1 		$0 Hold
10,000
– – ﹤0.01% 7376
2019
Q4 		$0 Hold
10,000
– – ﹤0.01% 7440
2019
Q3 		$0 Buy
+10,000
New – ﹤0.01% 7518
2017
Q1 		– Sell
-338
Closed -$2K – 7117
2016
Q4 		$2K Buy
+338
New +$2.03K ﹤0.01% 6518
2016
Q1 		– Sell
-75
Closed – – 7149
2015
Q4 		$0 Buy
+75
New +$404 ﹤0.01% 7288
2013
Q3 		– Sell
-97
Closed – – 6570
2013
Q2 		$0 Buy
+97
New +$361 ﹤0.01% 5958

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Royal Bank of Canada's SVA Position: Q1 2026 in Review

Royal Bank of Canada increased its Sinovac Biotech, Ltd (SVA) stake by 0.24% in Q1 2026, adding 1 share and bringing the position to 426 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7893.

Royal Bank of Canada first reported a position in SVA in Q2 2013 and has held it in 22 quarters since. The position peaked at $2K in Q4 2016. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

  • Royal Bank of Canada held 426 shares of Sinovac Biotech, Ltd worth $0 as of Q1 2026.
  • Royal Bank of Canada bought 1 Sinovac Biotech, Ltd share in Q1 2026.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7893 holding.
  • Royal Bank of Canada first reported a position in Sinovac Biotech, Ltd in Q2 2013 and has held it in 22 quarters since.
  • Royal Bank of Canada's Sinovac Biotech, Ltd position peaked at $2K in Q4 2016.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.